MaaT Pharma Statistics

Total Valuation

MaaT Pharma has a market cap or net worth of EUR 93.79 million. The enterprise value is 89.59 million.

Market Cap	93.79M
Enterprise Value	89.59M

Important Dates

The last earnings date was Wednesday, March 26, 2025.

Earnings Date	Mar 26, 2025
Ex-Dividend Date	n/a

Share Statistics

MaaT Pharma has 16.12 million shares outstanding. The number of shares has increased by 14.95% in one year.

Current Share Class	n/a
Shares Outstanding	16.12M
Shares Change (YoY)	+14.95%
Shares Change (QoQ)	+14.25%
Owned by Insiders (%)	1.46%
Owned by Institutions (%)	17.39%
Float	3.21M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	29.16
PB Ratio	9.07
P/TBV Ratio	10.95
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-3.10
EV / Sales	27.86
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-3.93

Financial Position

The company has a current ratio of 1.90, with a Debt / Equity ratio of 1.54.

Current Ratio	1.90
Quick Ratio	1.81
Debt / Equity	1.54
Debt / EBITDA	n/a
Debt / FCF	-0.70
Interest Coverage	-32.75

Financial Efficiency

Return on equity (ROE) is -187.68% and return on invested capital (ROIC) is -58.41%.

Return on Equity (ROE)	-187.68%
Return on Assets (ROA)	-43.64%
Return on Invested Capital (ROIC)	-58.41%
Return on Capital Employed (ROCE)	-118.75%
Revenue Per Employee	51,048
Profits Per Employee	-458,794
Employee Count	60
Asset Turnover	0.08
Inventory Turnover	12.71

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -33.41% in the last 52 weeks. The beta is 0.13, so MaaT Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.13
52-Week Price Change	-33.41%
50-Day Moving Average	6.24
200-Day Moving Average	7.24
Relative Strength Index (RSI)	43.87
Average Volume (20 Days)	7,669

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, MaaT Pharma had revenue of EUR 3.22 million and -28.90 million in losses. Loss per share was -2.21.

Revenue	3.22M
Gross Profit	1.60M
Operating Income	-28.43M
Pretax Income	-28.90M
Net Income	-28.90M
EBITDA	-28.20M
EBIT	-28.43M
Loss Per Share	-2.21

Full Income Statement

Balance Sheet

The company has 20.15 million in cash and 15.96 million in debt, giving a net cash position of 4.20 million or 0.26 per share.

Cash & Cash Equivalents	20.15M
Total Debt	15.96M
Net Cash	4.20M
Net Cash Per Share	0.26
Equity (Book Value)	10.34M
Book Value Per Share	0.74
Working Capital	13.08M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -22.04 million and capital expenditures -753,000, giving a free cash flow of -22.79 million.

Operating Cash Flow	-22.04M
Capital Expenditures	-753,000
Free Cash Flow	-22.79M
FCF Per Share	-1.41

Full Cash Flow Statement

Margins

Gross Margin	49.81%
Operating Margin	-883.96%
Pretax Margin	-898.76%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

MaaT Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-14.95%
Shareholder Yield	-14.95%
Earnings Yield	-30.82%
FCF Yield	-24.30%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

MaaT Pharma has an Altman Z-Score of -0.74. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.74
Piotroski F-Score	n/a